Theneo5HT3R3SNF5HT3R3signalingpathwaypromotes

**Paula Ramirez, Laura Baker MD, Charlotte Jordan,
Rachel Hughes, Becky May, David Newman**

Florida State University

Activation of the SNF5HT3R3 Signaling Pathway Although SNF5HT3R1, SNF5HT3R2, and SNF5HT3R3 signaling pathways play important roles in the regulation of cell proliferation, migration, and invasion in human colon carcinoma, there are no consensus on the molecular mechanisms of the action of these pathways. Several cellular systems have been studied to explain the mechanisms of action of SSR, including the regulation of tumor growth and metastasis [8,9]. SSR can induce apoptosis in the colon tumor cells and tumor cells by inducing their growth factors and cytokines, which in turn promote the invasion of tumor cells by inducing the formation of artificial tumor cells that respond to SSR. This has been shown to be accomplished through the activation of NF-jB, which can activate the cell growth factors such as tumor growth factor-1 (TGF- beta; see also Figure S6). SSR can induce apoptosis in breast cancer cells and metastases by inducing their growth factors and cytokines, which in turn promote the formation of artificial tumors that respond to SSR. To investigate the mechanism of SSR, we analyzed the effect of SSR on the expression of caspase-3 (Caspase-3) in human colon cancer cells. SSR has potent apoptosis in the breast cancer cell line FUEC-4. SSR can induce apoptosis in both breast cancer and tumor cells by inducing their growth factors and cytokines, which in turn promote the formation of the artificial tumor cells that respond to SSR. In the present study we aimed to investigate the mechanism of SSR on the effect of SSR on the Caspase-3 expression in the colon cancer cell line BHI-4 and the effect of SSR on the Caspase-3 expression in the mammary carcinoma cell line KCM-1. Caspase-3 is a key component of the SSR pathway [6]. It translates into cytoplasm in response to SSR and is required for activation of the caspase-3 signaling pathway. SSR can induce apoptosis in the colon cancer cell line FUEC-4, but not in the tumor cell line KCM-1. SSR has potentapoptosis in the breast cancer cell line KCM-1, but not in the tumor cell line IAP-1 (see also Figure S6). SSR can induce apoptosis in breast cancer cells and metastases by inducing their growth factors and cytokines, which in turn promote the formation of artificial tumors that respond to SSR. While SSR can induce apoptosis in the colon cancer cell line KCM-1, SSR can not induce apoptosis in the tumor cell line BHI-4 or the tumor cell line KCM-1. SSR can induce apoptosis in the colon cancer cell line KCM-1, but not in the tumor cell IAP-1. SSR can induce apoptosis in the colon cancer cell line KCM-1, but not in the tumor cell line KCM-1. SSR can induce apoptosis in the colon cancer cell line KCM-1, but not in the tumor cell line KCM-1. Caspase-3 expression in the colon cancer cell line KCM-1 and KCM-1 is significantly down-regulated in the breast cancer cell line KCM-1 and KCM-1. SSR can induce apoptosis in the colon cancer cell line KCM-1 and KCM-1. SSR can induce apoptosis in the colon cancer cell line KCM-1 and KCM-1. In order to determine the mechanisms of SSR on the pathogenesis of colon cancer cell lines, we performed an in vivo study in which SSR (5 mg/kg) or a combination of SSR and SSR- sulfamethazine (SSR) was administered orally (5 mg/kg) or in a small amount (0.2 mg/kg) in a randomized, double- blind (RT) manner. SSR and SSR-sulfamethazine, SS